Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer

Sacituzumab govitecan (SG) is an anti-Trop-2 antibody-drug conjugate with an SN-38 payload. In the ASCENT study, patients with metastatic triple-negative breast cancer (mTNBC) relapsed/refractory to ≥2 prior chemotherapy regimens (≥1 in the metastatic setting), received SG or single-agent treatment...

Descripción completa

Detalles Bibliográficos
Autores principales: Rugo, Hope S., Tolaney, Sara M., Loirat, Delphine, Punie, Kevin, Bardia, Aditya, Hurvitz, Sara A., O’Shaughnessy, Joyce, Cortés, Javier, Diéras, Véronique, Carey, Lisa A., Gianni, Luca, Piccart, Martine J., Loibl, Sibylle, Goldenberg, David M., Hong, Quan, Olivo, Martin, Itri, Loretta M., Kalinsky, Kevin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9424318/
https://www.ncbi.nlm.nih.gov/pubmed/36038616
http://dx.doi.org/10.1038/s41523-022-00467-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9424318/
https://www.ncbi.nlm.nih.gov/pubmed/36038616
http://dx.doi.org/10.1038/s41523-022-00467-1

Ejemplares similares